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Impact of the ASA Physical Status Score on Adjuvant 
Chemotherapy Eligibility and Survival of Upper Tract Urothelial 
Carcinoma Patients: a Multicenter Study
The aim of the present multi-institutional study was to assess the influence of the 
American Society of Anesthesiologists Physical Status (ASA-PS) classification on adjuvant 
chemotherapy eligibility and survival in a multi-institutional cohort of patients treated 
with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). We 
retrospectively reviewed data from 416 patients who underwent RNU for UTUC at four 
Korean institutions between 2001 and 2013. The ASA-PS classification was obtained from 
the anesthesia chart. Locally advanced UTUC was defined as ≥ pT3 and/or pN1 disease. 
The influence of ASA-PS score on survival was evaluated by Kaplan-Meier analyses and a 
multivariate Cox regression model. Patients with a higher ASA-PS class were less likely to 
be eligible for adjuvant chemotherapy in locally advanced UTUC (P = 0.016). Kaplan-Meier 
estimates showed that the high-risk ASA-PS group has a poorer overallsurvival (OS) and 
cancer-specific survival (CSS) compared to low risk ASA-PS groups in both the total and 
locally advanced UTUC cohorts. Based on multivariate Cox regression analysis, the high-
risk ASA-PS category was an independent predictor for overall mortality (OM) (hazard ratio 
[HR], 1.919; 95% confidence interval [CI], 1.017–3.619; P = 0.044) and cancer-specific 
mortality (CSM) (HR, 2.120; 95% CI, 1.023–4.394; P = 0.043). In conclusion, high-risk 
ASA-PS score was independently associated with a lower survival rate in patients with 
UTUC after RNU. However, the influence of ASA-PS classification on survival was limited 
to locally advanced UTUC. The lower eligibility of patients in the high-risk ASA category for 
adjuvant chemotherapy may contribute to the lower survival rate in this group.
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Urothelial Carcinoma; Survival
Ho Won Kang,1 Sung Pil Seo,1  
Won Tae Kim,1 Yong-June Kim,1  
Seok Joong Yun,1 Sang-Cheol Lee,1 
Young Deuk Choi,2 Yun-Sok Ha,3  
Tae-Hwan Kim,3 Tae Gyun Kwon,3  
Seok-Soo Byun,4 Seong Uk Jeh,5  
and Wun-Jae Kim1
1Department of Urology, Chungbuk National 
University College of Medicine, Cheongju, Korea;
2Department of Urology, Gangnam Severance 
Hospital, Urological Science Institute, Yonsei 
University College of Medicine, Seoul, Korea;
3Department of Urology, Kyungpook National 
University School of Medicine, Daegu, Korea;
4Department of Urology, Seoul National University 
Bundang Hospital, Seongnam, Korea;
5Department of Urology, Gyeongsang National 
University School of Medicine, Jinju, Korea
Received: 29 July 2016
Accepted: 16 October 2016
Address for Correspondence:
Wun-Jae Kim, MD
Department of Urology, Chungbuk National University College 
of Medicine and Institute for Tumor Research, 776 1-Sunhwan-
ro, Seowon-gu, Cheongju 28644, Republic of Korea
E-mail: wjkim@chungbuk.ac.kr
Funding: This research was supported by Basic Science 
Research Program through the National Research Foundation of 
Korea (NRF) funded by the Ministry of Science, ICT & Future 
Planning (No. NRF-2014R1A2A1A09006983), and by a research 
grant from Chungbuk National University in 2014.
This work was also supported by the Technological Innovation  
R&D Program (S2316843) funded by the Small and Medium 
Business Administration (SMBA, Daejeon, Korea).
https://doi.org/10.3346/jkms.2017.32.2.335 • J Korean Med Sci 2017; 32: 335-342
INTRODUCTION
Upper tract urothelial cancer (UTUC) is an aggressive disease 
associated with significant morbidity and mortality (1). At pre­
sentation, 30% of patients demonstrate invasive and/or locally 
advanced disease, 30%–40% have regional lymph node (LN) 
involvement, and 20% harbor metastatic disease (2). Radical 
nephroureterectomy (RNU) with bladder cuff excision is con­
sidered the standard of care for most invasive UTUCs, but dis­
tant relapses are common following surgery for locally advanc­
ed, high­grade disease (3). For patients with advanced disease, 
systemic recurrence and progression rates range from 45%–60% 
(2). The 5­year survival rates for patients classified with pT2­ and 
pT3­stage disease are 73% and 40%, respectively, and the medi­
an survival for patients with T4 stage disease is approximately 6 
months. Given the inadequacy of radical surgery alone for pa­
tients with regionally advanced UTUC, a multimodal approach 
that includes perioperative chemotherapy regimens seems to 
be a promising approach (4). Systemic chemotherapy in an ad­
juvant or neoadjuvant setting with local tumor control was ad­
opted in the 2013 National Comprehensive Cancer Network 
guideline (5). Nevertheless, there is lack of consensus regarding 
the accurate identification of patients who may benefit from 
adjuvant chemotherapy and determine what factors are barri­
ers to systemic therapy eligibility. Renal insufficiency following 
RNU and nephrotoxic chemotherapy regimen seem to be chal­
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lenges preventing the effective delivery of cisplatin­based che­
motherapy (6­8). Although general condition and systemic ill­
ness could be barriers for perioperative chemotherapy and also 
significant determinants of survival, the prognostic influences 
of comorbidity/performance indices on eligibility for adjuvant 
chemotherapy and survival in patients with UTUC remains un­
clear.
 The American Society of Anesthesiologists Physical Status 
(ASA­PS) classification system was first introduced in 1940 and 
has been updated and now includes a 6­point scale, ranging from 
a healthy person (class 1) to one with a severe systemic disorder 
that is a constant threat to life (class 4). Class 5 was representing 
for moribund persons not expected to survive 24 hours, with or 
without surgery and the 6 class is now used for declared brain­
dead organ donors (9). The ASA­PS classification was originally 
designed as a standardized way for anesthesiologists to convey 
information about the patient’s overall health status that allows 
outcomes to be stratified by a global assessment of their illness 
severity. In practice, however, the ASA­PS score is frequently 
used to explicitly or implicitly estimate operative risk because it 
is the only instance for which overall preoperative condition is 
consistently preoperatively recorded for a large number of pa­
tients, and it correlates well with surgical mortality and morbid­
ity (9). Moreover, the ASA­PS system has a unique ability to quick­
ly and concisely summarize multiple patient characteristics (10).
 In this study, we tested our hypothesis that the ASA­PS sys­
tem, as an assessment of systemic comorbidity/performance 
indices, may be associated with eligibility for adjuvant chemo­
therapy and potentially unfavorable survival outcomes in pa­
tients with UTUC who underwent RNU in 4 centers in Korea.
 
MATERIALS AND METHODS
Study population and data collection
We performed a retrospective analysis of 505 patients treated 
with RNU for UTUC at four academic centers in Korea. The da­
tabase listed patient characteristics including age, sex, body 
mass index (BMI), bladder cancer history, surgical approach 
(open vs. laparoscopic), tumor stage, grade, LN status (lympho­
vascular invasion), concomitant carcinoma in situ, tumor loca­
tion, use of adjuvant chemotherapy, prior endoscopic therapy, 
tumor multifocality, disease recurrence, and mortality from 
UTUC. The ASA­PS classification was obtained from the anes­
thesia chart. All of the patients who had complete follow­up 
data available were considered for the analysis. A computerized 
databank was generated for the data transfer. After combining 
the data sets, reports were generated for each variable to identi­
fy inconsistencies and other data integrity problems. Prior to 
the final analysis, the database was frozen, and the final data set 
was produced for the current analysis (by HYS). Patients with 
an incomplete data set or those who received neoadjuvant che­
mo/radiotherapy were excluded. To avoid biasing the survival 
estimates, we also excluded patients with a history of radical 
cystectomy (RC) for treatment of previous or concomitant mus­
cle­invasive bladder tumor, distant metastases at diagnosis, and 
perioperative mortality within 1 month. The final study group 
comprised 416 patients.
Protocols for surgery and pathologic evaluation
RNU was performed by a standard double­access procedure 
(11). The kidney, ureter, and a bladder cuff were excised en bloc. 
The hilar and regional LNs adjacent to the ipsilateral great ves­
sel were generally resected if they were palpable intraoperative­
ly or suspected based on preoperative imaging. All surgical spec­
imens were processed according to the standard pathologic pro­
cedures at each institution. The tumors were assessed accord­
ing to the 2002 American Joint Committee on TNM classifica­
tion (12). Tumor grading was performed using the 1998 World 
Health Organization/International Society of Urologic Patholo­
gy consensus classification (13). Tumor multifocality was defin­
ed as the synchronous presence of multiple tumors in the renal 
pelvis or ureter. Locally advanced UTUC was defined as ≥ pT3 
and/or pN1 disease.
Follow-up protocol
After surgery, each patient was monitored according to the stan­
dard guidelines (14). In general, patients were evaluated every 
3–4 months for the first year following RNU, every 6 months 
from the second through fifth years, and annually thereafter. 
The follow­up included history taking, physical examination, 
routine blood and serum chemistry lab work, urinary cytology, 
chest radiography, cystoscopic evaluation of the urinary blad­
der, and radiographic evaluation of the contralateral upper uri­
nary tract. Elective bone scans, chest computed tomography, or 
magnetic resonance imaging was only performed when clini­
cally indicated. Adjuvant chemotherapy was administered at 
the surgeons’ discretion based on tumor stage and overall health 
status.
 Deaths were determined by reviewing medical records, and 
time to cancer­specific mortality (CSM) was calculated as the 
time from surgery to the date of cancer­attributable mortality. 
Any patients who died without any proof of metastasis or recur­
rence were considered to have cancer­independent mortality 
(CIM).
Statistical analysis
Continuous variables are shown as medians and interquartile 
ranges (IQRs). Differences in variables with continuous distri­
butions across dichotomous categories were assessed using 
Mann­Whitney U tests. Fisher exact and χ2 tests were used to 
evaluate associations between categorical variables. Cohorts 
were defined by ASA­PS classification, and then pathologic re­
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sults and adjuvant chemotherapy eligibility were compared. 
Kaplan­Meier curves for overall survival (OS) and cancer­spe­
cific survival (CSS) were generated and compared using log­
rank tests based on ASA­PS classification. A subgroup analysis 
for locally advanced UTUC patients who may benefit from ad­
juvant chemotherapy was also performed. Univariate and mul­
tivariate survival analyses were performed using the Cox pro­
portional hazard regression model.
 Differences were considered significant at P < 0.05, and all 
reported P values are 2­sided. Analyses were performed using 
SPSS 20.0 software (IBM Corp., Armonk, NY, USA).
Ethics statement
The study was carried out in agreement with the applicable laws 
and regulations, good clinical practices, and ethical principles 
as described in the Declaration of Helsinki. The Institutional 
Review Board of Chungbuk National University approved this 
study protocol (Approval No.: GR2014­12­009). Informed con­
sent was waived by the board.
RESULTS
Baseline characteristics
The clinical and pathologic characteristics of the patient cohort 
are shown in Table 1.
 Overall, 259 (62.3%) patients underwent laparoscopic neph­
rectomy, and the remaining 167 (38.0%) patients underwent 
open RNU. The stage distribution was 5.5% Ta, 1.9% Tis, 32.7% 
T1, 26.2% T2, 31.5% T3, and 2.2% T4. Overall, 75.2% had high­
grade UTUC. A total of 207 (49.7%) patients underwent concur­
rent regional LN dissection and 18 (4.3%) had metastasis to re­
gional LNs. Adjuvant chemotherapy was administered to 62 
(14.9%) patients including 17 with localized but high­risk UTUC 
and 45 patients with locally advanced UTUC (defined as ≥ pT3 
and/or pN1 disease).
ASA-PS score and adjuvant chemotherapy eligibility
Of the 416 patients included in this study, 118 (28.4%), 262 (63.0%), 
and 36 (8.7%) were assigned to the score 1, 2, and 3 groups, re­
spectively (Table 1). Patient age was significantly increased with 
higher degrees of ASA­PS classification (P < 0.001) (Table 2). In 
addition, patients placed in higher ASA­PS classes were less like­
ly to be eligible for adjuvant chemotherapy in the total cohort 
(P = 0.029) (Table 2) and in the subgroup analysis limited to pa­
tients with locally advanced UTUC (P = 0.007) (Table 3). There 
were no significant differences according to ASA­PS classifica­
tion in terms of other clinicopathologic characteristics includ­
ing sex, history of previous or concomitant bladder cancer, patho­
logic stage or grade, LN status (lymphovascular invasion), tu­
mor necrosis, concomitant carcinoma in situ, tumor location, 
or multifocality (all P > 0.05) (Table 2).
ASA-PS score and survival in patients treated with RNU for 
UTUC
The median follow­up period of the study cohort was 30 months 
(IQR 15 to 52 months). During follow­up, 62 (14.9%) patients 
died of UTUC. Kaplan­Meier estimates showed that high­risk 
group (ASA 3) had a poorer OS and CSS compared to the low­
risk group (ASA 1–2) in the total and locally advanced UTUC 
cohorts (Fig. 1A and 1B). However, there was no significant sur­
vival impact of ASA­PS score on OS or CSS in patients with lo­
calized UTUC (P = 0.475 and P = 0.399, respectively) (Fig. 1C). 
Multivariate Cox regression analysis revealed that age (hazard 
ratio [HR], 1.033; 95% confidence interval [CI], 1.004–1.062; P =  
0.025), lower BMI (HR, 1.675 95% CI, 1.020–2.753; P = 0.042), 
tumor size (HR, 1.008; 95% CI, 1.001–1.015; P = 0.020), locally 
advanced stage (HR, 2.482 95% CI, 1.415–4.353; P = 0.002), lym­
phovascular invasion (HR, 1.991; 95% CI, 1.180–3.360; P = 0.010), 
Table 1. Clinicopathologic characteristics of patients
Parameters Value
Age, mean ± SD, yr 66.3 ± 10.7
Follow-up period, median (IQR), mon 30.0 (15.0–52.0)
BMI, median (IQR), kg/m2 23.9 (21.6–25.8)
Sex, No. (%)
   Male
   Female 
289 (69.5)
127 (30.5)
ASA-PS classification, No. (%)
   Class 1
   Class 2
   Class 3
118 (28.4)
262 (63.0)
36 (8.7)
Nephrectomy methods, No. (%)
   Open procedure
   Laparoscopic procedure 
167 (38.0)
273 (62.0)
Previous or concomitant BC, No. (%)
   Previous BC history
   Concomitant BC
87 (20.9)
41 (9.9)
52 (12.5)
Tumor location, No. (%)
   Renal pelvis
   Ureter
   Both
143 (34.4)
210 (50.5)
63 (15.1)
Pathologic T stage, No. (%)
   Tis
   Ta
   T1
   T2
   T3
   T4
8 (1.9)
23 (5.5)
136 (32.7)
109 (26.2)
131 (31.5)
9 (2.2)
Pathologic N stage, No. (%)
   Nx
   N0
   N1–2
209 (50.2)
189 (45.4)
18 (4.3)
Tumor grade, No. (%)
   Low
   High
103 (24.8)
313 (75.2)
Concomitant CIS, No. (%) 30 (7.2)
Lymphovascular invasion, No. (%) 72 (17.3)
Positive surgical margin, No. (%) 22 (5.3)
Adjuvant chemotherapy, No. (%) 62 (14.9)
SD = standard deviation, IQR = interquartile range, BMI = body mass index, ASA-
PS = American Society of Anesthesiologists Physical Status, BC = bladder cancer, 
CIS = carcinoma in situ.
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and high ASA­PS score (HR, 1.919; 95% CI, 1.017–3.619; P = 0.044) 
were independent predictors of overall mortality (OM) (Table 4). 
Moreover, lower BMI (HR, 1.933; 95% CI, 1.115–3.350; P = 0.019), 
locally advanced stage (HR, 2.703; 95% CI, 1.417–5.157; P = 0.003), 
lymphovascular invasion (HR, 2.600; 95% CI, 1.469–4.602; P =  
0.001), positive surgical margin (HR, 2.110; 95% CI, 1.025–4.342; 
P = 0.043), and high ASA­PS score (HR, 2.120; 95% CI, 1.023–
4.394; P = 0.043) were independent predictors of CSM (Table 5).
DISCUSSION
In this study, we evaluated the prognostic value of the ASA­PS 
scoring system on adjuvant chemotherapy eligibility and sur­
vival in a multi­center cohort of patients with UTUC treated with 
RNU. Our results show that the ASA­PS classification as an as­
sessment of systemic comorbidity/performance indices was 
associated with adjuvant chemotherapy eligibility and poten­
tially unfavorable survival in this patient group.
 Comorbidity and performance status indices are useful clini­
cal tools to estimate the risk of comorbidities, which may guide 
decision making regarding operative procedures or multimodal 
therapy approaches. The most commonly used comorbidity in­
dices in the literature are the Charlson comorbidity index (CCI, 
age­adjusted Charlson comorbidity index [ACCI]), the ASA­PS, 
the Adult Comorbidity Evaluation­27 (ACE­27), the Eastern Co­
operative Oncology Group (ECOG) performance status, and the 
Karnofsky Performance Status scale (KPS). The ASA­PS score 
was first described in 1940 by Saklad (15) and is the oldest eval­
Table 2. Comparison of clinicopathologic parameters according to ASA-PS classification in UTUC patients treated with RNU
Parameters
ASA-PS classification
P value
Class 1 Class 2 Class 3
No. of patients 118 262 36 -
Age (mean ± SD), yr 62.4 ± 11.1 67.3 ± 10.1 72.0 ± 9.5 0.001*
Follow-up period, median (IQR), mon 34 (19.8–58.5) 27 (15.0–51.0) 27.5 (11.5–49.8) 0.548*
BMI, median (IQR), kg/m2 23.7 (21.5–25.5) 23.9 (21.9–26.0) 22.7 (20.4–27.1) -
Gender, No. (%)
   Male
   Female
84 (71.2)
34 (28.8)
179 (68.3)
83 (31.7)
26 (72.2)
10 (27.8)
0.796†
Previous or concomitant BC, No. (%) 30 (25.4) 51 (19.5) 6 (16.7) 0.337†
Tumor location, No. (%)
   Renal pelvis
   Ureter
   Both
46 (39.0)
54 (45.8)
18 (15.3)
87 (33.2)
139 (53.1)
36 (13.7)
10 (27.8)
17 (47.2)
9 (25.0)
0.300†
Pathologic T stage, No. (%)
   Tis
   Ta
   T1
   T2
   T3
   T4
4 (3.4)
6 (5.1)
40 (33.9)
24 (20.3)
40 (33.9)
4 (3.4)
4 (1.5)
16 (6.1)
85 (32.4)
74 (28.2)
79 (30.2)
4 (1.5)
0 (0.0)
1 (2.8)
11 (30.6)
11 (30.6)
12 (33.3)
1 (2.8)
0.722†
Pathologic N1–2, No. (%) 5 (4.2) 13 (5.0) 0 (0.0) 0.644†
Tumor grade, No. (%)
   Low
   High
29 (23.7)
90 (76.3)
70 (26.7)
192 (73.3)
5 (13.9)
31 (86.1)
0.236†
-
0.375†
Concomitant CIS, No. (%) 11 (9.3) 17 (6.5) 2 (5.6) 0.291†
Lymphovascular invasion, No. (%) 15 (12.7) 49 (18.7) 8 (22.2) 0.259†
Positive surgical margin, No. (%) 8 (6.8) 11 (4.2) 3 (8.3) 0.404†
Adjuvant chemotherapy, No. (%) 24 (20.3) 37 (14.1) 1 (2.8) 0.029†
ASA-PS = American Society of Anesthesiologists Physical Status, UTUC = upper tract urothelial carcinoma, RNU = radical nephroureterectomy, SD = standard deviation, IQR =  
interquartile range, BMI = body mass index, BC = bladder cancer, CIS = carcinoma in situ.
P value was based on the *Mann-Whitney U test or †Fisher exact test.
Table 3. Adjuvant chemotherapy status according to ASA-PS classification between the locally advanced and localized UTUC
ASA-PS classification
Localized UTUC Locally advanced UTUC
Not administered Administered P value Not administered Administered P value
1 68 (93.2) 5 (6.8) 0.694* 26 (73.6) 19 (42.2) 0.007*
2 166 (93.8) 11 (6.2) 59 (69.4) 26 (30.6)
3 22 (95.7) 1 (4.3) 13 (100.0) 0 (0.0)
ASA-PS = American Society of Anesthesiologists Physical Status, UTUC = upper tract urothelial carcinoma.
*P values were calculated with the Fisher exact test.
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uation score that assesses perioperative risk. Although the ASA­
PS score was originally designed as a uniform system for anes­
thesiologists to convey information about the patient’s overall 
health status, it has been shown to accurately predict perioper­
ative morbidity and mortality (9,16,17). Furthermore, numer­
ous studies have suggested that the ASA­PS score as an assess­
ment of systemic comorbidity/performance indices may pro­
vide prognostic information in many cancer surgeries includ­
ing urological malignancies such as prostate, bladder, and renal 
cell carcinoma. Anudeep and colleagues found that ASA­PS 
score was associated with OS after minimally invasive partial 
nephrectomy for renal cell carcinoma (18). The survival impact 
of ASA classification was also recognized in the radical prosta­
tectomy setting (19­21). The predictive capacity of the ASA­PS 
scoring with regard to OM and CSM in patients who underwent 
RC for bladder cancer remains unclear (22­24). Several studies 
have also supported the prognostic role of comorbidity/perfor­
mance indices in patients with UTUC after RNU. For example, 
a large national multi­center collaborative study found that the 
ASA classification significantly correlated with CSS after RNU 
for UTUC. In this study, the 5­year CSS differed significantly 
between ASA 1, 2, and 3 patients (83.8%, 76.9%, and 70.6%, re­
Fig. 1. Kaplan-Meier analysis of OS and CSS in (A) total cohort, (B) subgroup with locally advanced tumor, and (C) subgroup with localized tumor in patients treated with RNU 
for UTUC.
OS = overall survival, CSS = cancer-specific survival, RNU = radical nephroureterectomy, UTUC = upper tract urothelial carcinoma, ASA-PS = American Society of Anesthesiol-
ogists Physical Status.
Low ASA-PS score (class 1-2)
High ASA-PS score (class 3)
Ca
nc
er
 s
pe
ci
fic
 s
ur
vi
va
l (
%
)
Time (months after surgery)
Number at risk
   Group: 0 250 212 163 107 72 54 33 21 10 8 5 2 0 0
   Group: 1 23 19 16 14 10 5 3 3 1 0 0 0 0 0
 0 12 24 36 48 60 72 84 96 108 120 132 144 156
100
90
80
70
60
50
40
30
20
10
0
log-rank, P = 0.437
Ov
er
al
l s
ur
vi
va
l (
%
)
Time (months after surgery)
Number at risk
   Group: 0 250 212 163 107 72 54 33 21 10 8 5 2 0 0
   Group: 1 23 19 16 14 10 5 3 3 1 0 0 0 0 0
 0 12 24 36 48 60 72 84 96 108 120 132 144 156
100
90
80
70
60
50
40
30
20
10
0
log-rank, P = 0.224
Ca
nc
er
 s
pe
ci
fic
 s
ur
vi
va
l (
%
)
Time (months after surgery)
Number at risk
   Group: 0 129 101 63 43 31 25 17 8 1 1 0
   Group: 1 13 8 3 2 1 0 0 0 0 0 0
 0 12 24 36 48 60 72 84 96 108 120
100
90
80
70
60
50
40
30
20
log-rank, P = 0.004
Ov
er
al
l s
ur
vi
va
l (
%
)
Time (months after surgery)
Number at risk
   Group: 0 129 101 63 43 31 25 17 8 1 1 0
   Group: 1 13 8 3 2 1 0 0 0 0 0 0
 0 12 24 36 48 60 72 84 96 108 120
100
80
60
40
20
0
log-rank, P = 0.001
Ov
er
al
l s
ur
vi
va
l (
%
)
Time (months after surgery)
Number at risk
   Group: 0 379 313 226 150 103 79 50 29 11 9 5 2 0 0
   Group: 1 36 27 19 16 11 5 3 3 1 0 0 0 0 0
 0 12 24 36 48 60 72 84 96 108 120 132 144 156
100
90
80
70
60
50
40
30
20
10
0
log-rank, P = 0.006
Ca
nc
er
 s
pe
ci
fic
 s
ur
vi
va
l (
%
)
Time (months after surgery)
Number at risk
   Group: 0 379 313 226 150 103 79 50 29 11 9 5 2 0 0
   Group: 1 36 27 19 16 11 5 3 3 1 0 0 0 0 0
 0 12 24 36 48 60 72 84 96 108 120 132 144 156
100
90
80
70
60
50
40
30
20
10
0
log-rank, P = 0.002
A
B
C
Kang HW, et al. • ASA-PS Score and UTUC Prognosis
340  http://jkms.org https://doi.org/10.3346/jkms.2017.32.2.335
Table 4. Univariate and multivariate Cox regression models for the prediction of OM in UTUC patients treated with RNU
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.044 (1.020–1.069) < 0.001 1.033 (1.004–1.062) 0.025
Gender (female) 1.000 (0.635–1.576) 1.000 - -
ASA-PS score (ASA-PS 3) 2.084 (1.150–3.776) 0.015 1.919 (1.017–3.619) 0.044
BMI ( < 21.7 kg/m2) 2.031 (1.320–3.124) 0.001 1.675 (1.020–2.753) 0.042
Smoking history (yes) 0.994 (0.612–1.614) 0.980 - -
Tumor size 1.009 (1.003–1.015) 0.004 1.008 (1.001–1.015) 0.020
Multiplicity (yes) 1.590 (1.028–2.458) 0.037 1.380 (0.852–2.237) 0.191
Pathologic T stage ( ≥ T3) and/or N stage (N1–2) 3.267 (2.105–5.072) < 0.001 2.482 (1.415–4.353) 0.002
Grade (high) 2.723 (1.478–5.018) 0.001 1.603 (0.762–3.372) 0.213
Concomitant CIS (yes) 0.757 (0.275–2.085) 0.591 - -
Lymphovascular invasion (yes) 3.198 (2.061–4.960) < 0.001 1.991 (1.180–3.360) 0.010
Margin status (positive surgical margin) 4.178 (2.256–7.738) < 0.001 1.939 (0.968–3.885) 0.062
Adjuvant chemotherapy (yes) 1.799 (1.108–2.921) 0.017 1.047 (0.563–1.947) 0.885
OM = overall mortality, UTUC = upper tract urothelial carcinoma, RNU = radical nephroureterectomy, HR = hazard ratio, CI = confidence interval, ASA-PS = American Society 
of Anesthesiologists Physical Status, BMI = body mass index, CIS = carcinoma in situ.
Table 5. Univariate and multivariate Cox regression models for the prediction of CSM in UTUC patients treated with RNU
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.034 (1.008–1.061) 0.010 1.019 (0.988–1.051) 0.224
Gender (female) 1.192 (0.726–1.956) 0.487 - -
ASA-PS score (ASA-PS 3) 2.069 (1.051–4.071) 0.035 2.120 (1.023–4.394) 0.043
BMI ( < 21.7 kg/m2) 2.280 (1.413–3.677) 0.001 1.933 (1.115–3.350) 0.019
Smoking history (yes) 0.788 (0.444–1.397) 0.414 - -
Tumor size 1.008 (1.001–1.015) 0.021 1.008 (0.999–1.016) 0.075
Multiplicity (yes) 1.566 (0.958–2.559) 0.074 - -
Pathologic T stage ( ≥ T3) and/or N stage (N1–2) 4.511 (2.680–7.593) < 0.001 2.703 (1.417–5.157) 0.003
Grade (high) 4.385 (1.895–10.146) 0.001 2.571 (0.865–7.637) 0.089
Concomitant CIS (yes) 0.706 (0.220–2.269) 0.559 - -
Lymphovascular invasion (yes) 4.176 (2.588–6.737) < 0.001 2.600 (1.469–4.602) 0.001
Margin status (positive surgical margin) 4.559 (2.383–8.721) < 0.001 2.110 (1.025–4.342) 0.043
Adjuvant chemotherapy (yes) 2.355 (1.409–3.937) 0.001 1.417 (0.741–2.707) 0.292
CSM = cancer specific mortality, UTUC = upper tract urothelial carcinoma, RNU = radical nephroureterectomy, HR = hazard ratio, CI = confidence interval, ASA-PS = American 
Society of Anesthesiologists Physical Status, BMI = body mass index, CIS = carcinoma in situ.
spectively), and there was a threefold higher risk of OM and 
CSM at 5 years for patients rated as ASA 3 compared with ASA 1 
(25). In a recent study by Aziz et al. (26), 4 comorbidity indices 
(ASA­PS, CCI, ACCI, and ECOG­PS) were compared with re­
gard to recurrence­free survival (RFS), CSS, OS, and CIM. The 
ACCI and ECOG­PS were associated with RFS and CSS, where­
as the ASA­PS and ACCI scores were associated with CIM.
 Our results were similar to those described in previous stud­
ies in which a high ASA­PS score was associated with poorer 
survival in patients with UTUC who underwent RNU. However, 
the present study is unique for several reasons. We analyzed the 
survival influence of ASA­PS classification on the total cohort 
and also performed subgroup analyses for patients with local­
ized or locally advanced UTUC. We found that the survival in­
fluence of ASA­PS classification was limited to locally advanced 
UTUC. There were no significant differences with regard to OS 
or CSS between the low and high ASA­PS groups in patients 
with localized disease. Thus, radical surgery for localized UTUC 
might be reasonable and appropriate in patients with comor­
bidities. Of course, patients with a higher ASA have a higher need 
for preoperative optimization and critical postoperative care. 
Another strength of our study was that it considered a potential 
effect of adjuvant chemotherapy on survival outcomes in pa­
tients treated with RNU for UTUC. Such regimens could influ­
ence the long­term survival, especially CSS. Patients with a high­
er ASA­PS class tended to less likely to be prescribed adjuvant 
chemotherapy in the locally advanced stage, and decreased eli­
gibility for adjuvant chemotherapy in the high­risk ASA catego­
ry may influence poorer survival in these patients. Although 
there is lack of evidence regarding a survival benefit for periop­
erative platinum­based chemotherapy in patients with high­risk 
UTUC, adjuvant chemotherapy in this clinical setting may have 
an effect on survival given the high risk of relapse in patients with 
locally advanced UTUC (27).
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 Our study had several inherent weaknesses. There are limita­
tions due to the retrospective and multicentric nature of the study; 
we excluded patients for whom we could not obtain complete 
information, which could have led to selection bias. Moreover, 
we could not adjust for surgeons’ preferences, experience, or 
surgical techniques. There was also a lack of centralized patho­
logic review. However, all surgeons and pathologists operated 
at centers dedicated to the management of UTUC that followed 
the standard practice guidelines. Because comorbidities were 
measured using ASA­PS scores obtained from the anesthesia 
chart, an effect of interobserver variability in ASA scoring be­
tween different anesthesiologists at the four study institutions 
cannot be ruled out. Finally, we did not have access to data on 
perioperative renal function, which could be confounding fac­
tor affecting chemotherapy eligibility. Nevertheless, our study 
provides evidence supporting the use of the ASA­PS classifica­
tion to determine adjuvant chemotherapy eligibility and sur­
vival in patients with UTUC after RNU.
 In conclusion, high ASA­PS score was significantly associated 
with reduced eligibility for adjuvant chemotherapy and poorer 
survival of patients with UTUC after RNU. The subgroup analy­
sis revealed that the influence of ASA­PS score on survival was 
limited to patients with locally advanced UTUC. The lower fea­
sibility of adjuvant chemotherapy in the high­risk ASA category 
may contribute to the lower survival rate in this group.
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